Q-omics provides the consensus-scored SS18 profile across patient tissues and cancer cell-line models. SS18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SS18 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, SS18 protein abundance shows 23,707 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, LIHC, and LSCC as cancer lineages where SS18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SS18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SS18 survival associations across molecular data types. SS18 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SS18 RNA expression–survival associations across cancer types. High SS18 expression shows unfavorable associations in ACC, UVM, LGG, MESO and HNSC, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SS18 RNA expression.
This table summarizes SS18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SS18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SS18 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in LIHC, HNSC and BRCA. The LIHC box plot shows higher SS18 RNA expression in tumor versus normal tissue (log2 FC = +0.585, t-test p < 0.001).
This table shows molecular features associated with SS18 in patient tissues and cancer cell lines. In patient samples, SS18 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SS18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
